Articles tagged with Drug Studies
Researchers found that a combination of amyloid burden and blood markers of abnormal astrocyte activation can predict Alzheimer's disease progression. Testing for these biomarkers may help identify patients at risk, enabling earlier diagnosis and treatment.
A Canadian study found that eliminating out-of-pocket medication expenses for patients with cost-related nonadherence results in lower healthcare spending over three years. The analysis suggests that reducing medication costs could lead to significant savings in the overall healthcare system.
Researchers at UTHealth Houston are investigating the role of fibrin and fibrinogen in traumatic brain injury and hemorrhagic shock. The four-year grant will fund Phase II of a stem cell clinical trial evaluating whether mesenchymal stem cells reduce chronic neuroinflammatory response to traumatic brain injury.
The Alzheimer's disease development pipeline has seen an increase in promising therapies and pharma investment, driving momentum in clinical trials. The pipeline currently has 187 clinical trials, with recent FDA approvals for two disease-modifying therapies, and more on the way.
Researchers have identified a novel model and therapy to mitigate the development of REM sleep behavior disorder, which affects over 3 million Americans. Dual orexin receptor antagonists have been shown to significantly reduce dream enactment behaviors, providing a promising new treatment option.
Researchers developed an experimental drug, 32-134D, that inhibits HIF protein levels, reducing blood vessel production and leakiness in diabetic eyes. The study shows promising results in both human cell models and mice, suggesting a safer therapeutic approach for diabetic eye disease.
Researchers found that isosorbide mononitrate and cilostazol can safely improve debilitating outcomes after lacunar stroke. The two drugs were even more effective when used in combination, with participants showing significant improvements in thinking and memory skills, as well as quality of life.
A case study published in the Journal of Alzheimer's Disease reveals that lecanemab can lead to therapy-induced Aβ phagocytosis and multifocal intracerebral hemorrhage, highlighting a potential risk of brain damage and death. The study suggests that better biomarkers are needed to assess the extent of cerebral amyloid angiopathy.
A clinical trial of 403 patients found that ketamine treatment was non-inferior to ECT for treating non-psychotic treatment-resistant depression. Ketamine showed fewer side effects than ECT, with improved depressive symptoms and quality of life.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.
Researchers have developed a pharmacological treatment that improves cardiac function in patients with stiff-heart syndrome, a condition caused by amyloid protein deposition. The new drug reduces amyloid protein deposits and shows promise in reversing established disease symptoms.
A recent study published in The Lancet Neurology found that valbenazine significantly reduces chorea symptoms in patients with Huntington’s disease. The Phase III trial showed improvement as early as the second week of treatment, with consistently greater benefits compared to a placebo.
A multicentre, one-year real-world study found semaglutide effective for weight loss in patients with overweight and obesity, with 82% losing over 5% body weight. The medication also improved metabolic parameters, including blood pressure and cholesterol levels.
A new analysis of the SURMOUNT-1 study shows that tirzepatide improves body composition across a range of adult age groups, with significant reductions in fat mass. The treatment also results in a clinically meaningful improvement in body composition, with only one-quarter of weight lost being lean mass.
A large-scale clinical trial has found that spironolactone is an effective treatment for persistent acne in women, offering an alternative to antibiotics. The study, funded by the National Institute for Health and Care Research, recruited over 400 women with acne that had persisted for more than six months.
Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
The FDA approved Recarbrio, an antibiotic 40 times more expensive than a generic alternative, without adequate clinical trials showing substantial evidence of effectiveness. The approval has raised concerns that the agency's standards are being bypassed, and regulatory flexibility may have played a role in the decision.
A Phase 1 clinical trial has started to test the safety and tolerability of an experimental oral drug called HOPO 14-1 in healthy adults. The study aims to determine how the drug removes radioactive contaminants from the body, which can occur after nuclear accidents or exposure to dirty bombs.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
Clinical studies with children as participants often require more time, people, and resources than initially budgeted. The study found that pediatric clinical studies cost 59% more on average than the initial proposal, highlighting a need for accurate budgeting.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
The study used magnetic resonance imaging (MRI) to measure acute pressure changes inside the heart, discovering that pressure increases when patients receive a specific medication called adenosine. This technology can help doctors better diagnose and monitor patients with heart disease and heart failure.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer, with patients experiencing significantly improved progression-free survival. The median PFS was 11.3 months for those on nivolumab and ipilimumab alone, compared to not yet reached in the three-drug group.
A new study by Harvard T.H. Chan School of Public Health found significant racial inequalities in treatment for opioid use disorder, with White patients receiving medication up to 80% more frequently than Black and Hispanic patients. Despite similar numbers of healthcare visits, disparities persist.
Trials of Pfizer's maternal RSV vaccine suggest a possible increase in preterm births, prompting experts to call for further analysis and post-approval monitoring. The vaccine aims to protect infants from severe RSV illness, but its safety concerns have raised eyebrows.
A Cochrane review found that most antidepressants used to manage chronic pain lack sufficient evidence of their effectiveness, with only duloxetine showing reliable pain relief. The review also revealed that harms from many commonly recommended drugs have not been well studied, posing a global public health concern.
Researchers at McMaster University have found that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA). A systematic review of 14 clinical trials and analysis of data from various databases revealed solriamfetol to be the best option.
The study shows that zolbetuximab delays tumor progression and improves overall survival by 25% compared to chemotherapy alone. Patients with CLDN18.2-positive tumors responded well to the treatment, indicating a new clinically relevant biomarker for gastric cancer.
A retrospective cohort study of U.S. veterans found that adding a GLP1 receptor agonist to diabetes treatment reduced the risk of major adverse cardiovascular events and heart failure hospitalization by about 20% compared to DPP4 inhibitors. The study's findings will aid clinicians in choosing a diabetes drug regimen for older patients.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
A sharp increase in colchicine's price led to a 17% drop in its use and worsened disease control in gout patients. Patients turned to alternative medications with potentially different side effects, resulting in increased emergency department visits and specialist consultations.
Researchers identify OmpU protein variants associated with antimicrobial resistance in Vibrio cholerae bacteria. Understanding the evolutionary origins of AMR can inform the development of effective therapeutics against resistant infections.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
A pilot study found that high-dose tadalafil improved metabolic control and reduced hemoglobin A1c levels by 2.50 mmol/mol in patients with well-controlled type 2 diabetes. The treatment also showed increased blood flow, liver values, and metabolism.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
A recent study reveals that many children with attention-deficit/hyperactivity disorder (ADHD) are not receiving adequate treatment. The findings highlight the need for improved communication and access to outpatient mental health care for children with ADHD.
A preclinical study found that suvorexant reduced prescription opioid intake and helped protect against relapse in rats modeling opioid use disorder. The insomnia drug could offer a promising approach for the millions of people affected by OUD.
Researchers developed a biomarker signature test to predict which bladder cancer tumors will respond to immunotherapy, potentially improving survival rates. The study identified three types of responsive tumors and two non-responsive ones, providing insights into potential new treatments.
A new meta-analysis found that clozapine is associated with decreased insomnia and a lower risk of suicide in patients with schizophrenia. The study suggests that clozapine's ability to improve sleep quality may be linked to its reduced suicide risk, and highlights the importance of assessing and treating insomnia in these patients.
A new genetic therapy, BIIB080, has been shown to safely lower levels of the harmful tau protein in patients with Alzheimer's disease. The trial found a greater than 50% reduction in tau protein concentrations after 24 weeks in treatment groups.
A growing number of states have implemented policies to cover outpatient hemodialysis for undocumented immigrants with kidney failure. This expansion may be due to increased awareness of poor outcomes with emergency hemodialysis and advocacy efforts. The move towards covering dialysis in all 50 states is called for by experts, who also...
Research finds diclofenac's high variability in metabolism due to UGT2B17, a little-studied enzyme. The study suggests genetic testing and dose adjustments for specific populations can help minimize side effects.
Researchers have identified a possible way to help break the cycle between sleep disturbances and Alzheimer's disease. A small study found that people who took a sleeping aid experienced a drop in key Alzheimer's proteins.
A Phase I and Phase II clinical trial of the immunotherapy REGN5459 resulted in a 90.5 percent overall response rate among patients with relapsed multiple myeloma. The treatment is reasonably tolerated, with common side effects including cytokine release syndrome.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
A recent study published in the New England Journal of Medicine found that tranexamic acid did not reduce the need for blood transfusions or prevent maternal death in patients with increased risk for excessive bleeding after cesarean delivery. However, patients who received tranexamic acid had less need for additional medical intervent...
Two investigational drugs targeting the renin-angiotensin system were found ineffective in treating severe COVID-19. The study suggests that increasing levels of ANG II may contribute to lung damage and inflammation, but this theory was not supported by the trial results.
A new study found that more than 60% of parents had heard of PrEP, with relatively low levels of knowledge and high intentions to discuss and support their adolescents' PrEP care. The study highlights the importance of educating parents about PrEP to increase self-efficacy and uptake among at-risk populations.
A simulation modeling study finds that involuntary displacement worsens overdose and hospitalizations, decreases treatment initiation, and contributes to deaths. The study projects substantial increases in morbidity and mortality over a 10-year period in cities with such displacements.
Researchers have developed a glycine-based tripeptide that successfully treats nonalcoholic fatty liver disease in non-human primates and mice. The compound, DT-109, reverses fat buildup and prevents scarring by stimulating fatty acid degradation and antioxidant formation.
A study from Indiana University School of Medicine found that people with NAFLD have significantly decreased levels of the liver enzyme CYP2C19, which is important for medication processing. This decrease may lead to slower clearance of certain medications and reduced effectiveness of medicines like antidepressants and clopidogrel.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
Researchers have identified a promising new combination of drugs to treat juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer affecting children. The combination of 5-azacitidine and MEK inhibitor PD0325901 reduced cancerous stem cells and improved blood cell abnormalities.